
VistaGen Therapeutics VTGN
$ 0.16
-15.79%
VistaGen Therapeutics Total Non Current Liabilities | VTGN
Annual Total Non Current Liabilities VistaGen Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 249 K | 1.34 M | 4.24 M | 4.44 M | 4.16 M | 12.1 M | 8.73 M | 4.14 M | 2.9 M | 1.73 M | 2.17 M | 3.42 M | 7.86 M | 11 M | 2.87 M | 7.85 M | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.1 M | 249 K | 4.95 M |
Quarterly Total Non Current Liabilities VistaGen Therapeutics
| 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 K | 249 K | 607 K | 946 K | 1 M | 1.34 M | 1.56 M | 2 M | 2.51 M | 4.24 M | 3.62 M | 3.64 M | 4.13 M | 4.44 M | 3.64 M | 4.13 M | 4.44 M | 4.16 M | 4.75 M | 3.75 M | 3.75 M | 4.14 M | 11.9 M | 12 M | 12 M | 12.5 M | 12.7 M | 9.11 M | 8.01 M | 8.49 M | 8.25 M | 8.01 M | 4.14 M | 2.9 M | 2.65 M | 3.16 M | 2.04 M | 1.73 M | 2.4 M | 2.04 M | 1.73 M | 2.17 M | 1.14 M | 1.14 M | 994 K | 3.42 M | 909 K | 1.33 M | 3.42 M | 7.86 M | 10.9 M | 9.96 M | 9.96 M | 8.29 M | 8.29 M | 9.91 M | 9.45 M | 7.86 M | 3.94 M | 2.54 M | 2.54 M | 11 M | 3.07 M | 3.21 M | 3.21 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.7 M | 63 K | 4.85 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Vanda Pharmaceuticals
VNDA
|
16.6 M | $ 3.44 | -6.27 % | $ 203 M | ||
|
Voyager Therapeutics
VYGR
|
29.7 M | $ 1.52 | -5.9 % | $ 89.2 M | ||
|
Verrica Pharmaceuticals
VRCA
|
5.95 M | $ 2.74 | -5.03 % | $ 29.2 M | ||
|
Wave Life Sciences Ltd.
WVE
|
17.2 M | $ 2.56 | -6.07 % | $ 432 M | ||
|
XBiotech
XBIT
|
1.8 M | $ 1.75 | 4.17 % | $ 53.4 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
908 K | $ 1.37 | -7.43 % | $ 922 M | ||
|
Adial Pharmaceuticals
ADIL
|
665 K | $ 3.15 | -35.42 % | $ 2.11 M | ||
|
ADMA Biologics
ADMA
|
77.4 M | $ 13.18 | -1.2 % | $ 3.14 B | ||
|
Exicure
XCUR
|
25.2 M | $ 0.96 | -7.24 % | $ 6.05 M | ||
|
Xencor
XNCR
|
144 M | $ 33.48 | -1.56 % | $ 2.49 B | ||
|
Cortexyme
CRTX
|
86 M | - | -1.05 % | $ 67.1 M | ||
|
Daré Bioscience
DARE
|
5.95 M | $ 0.41 | -9.93 % | $ 4.58 M | ||
|
Fate Therapeutics
FATE
|
29.7 M | $ 0.92 | -9.07 % | $ 109 M | ||
|
Greenwich LifeSciences
GLSI
|
9.5 M | $ 19.09 | -3.54 % | $ 258 M | ||
|
Halozyme Therapeutics
HALO
|
2.3 B | $ 91.28 | -1.89 % | $ 10.9 B | ||
|
Hutchison China MediTech Limited
HCM
|
186 M | $ 13.18 | -2.04 % | $ 11.3 B | ||
|
Aptorum Group Limited
APM
|
306 K | - | - | $ 5.72 M | ||
|
iBio
IBIO
|
1.65 M | $ 0.83 | 3.01 % | $ 86.4 M | ||
|
Kodiak Sciences
KOD
|
149 M | $ 97.05 | -0.87 % | $ 5.16 B | ||
|
Karyopharm Therapeutics
KPTI
|
199 M | $ 0.02 | -56.5 % | $ 219 | ||
|
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M | ||
|
BioAtla
BCAB
|
24.7 M | $ 1.74 | 0.64 % | $ 102 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
2.56 M | - | - | $ 3.85 B | ||
|
UroGen Pharma Ltd.
URGN
|
260 M | $ 28.91 | -8.89 % | $ 1.39 B | ||
|
Catalyst Biosciences
CBIO
|
981 K | $ 13.01 | 0.74 % | $ 1.16 B | ||
|
ARCA biopharma
ABIO
|
1.31 M | - | 1052.0 % | $ 415 M | ||
|
ADiTx Therapeutics
ADTX
|
343 K | - | - | $ 374 | ||
|
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
3.42 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
3.86 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
3.49 M | - | 1.93 % | $ 17.4 M | ||
|
Aileron Therapeutics
ALRN
|
1.06 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
33.2 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
382 M | - | - | $ 5.18 B | ||
|
Athira Pharma
ATHA
|
16.9 M | - | - | $ 269 M | ||
|
AVROBIO
AVRO
|
43 K | - | 1083.1 % | $ 745 M | ||
|
AstraZeneca PLC
AZN
|
34.7 B | - | - | $ 96.9 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
EyePoint Pharmaceuticals
EYPT
|
20.9 M | $ 0.23 | -12.11 % | $ 16.8 K | ||
|
Bio-Path Holdings
BPTH
|
434 K | - | - | $ 100 K | ||
|
Cara Therapeutics
CARA
|
85 K | - | -3.03 % | $ 260 M | ||
|
ChromaDex Corporation
CDXC
|
9.95 M | - | -0.88 % | $ 598 M | ||
|
Caladrius Biosciences
CLBS
|
72 K | - | -16.75 % | $ 25.8 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
2 K | - | -5.98 % | $ 34.1 M | ||
|
Diffusion Pharmaceuticals
DFFN
|
480 K | - | 11.68 % | $ 8.97 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
5.24 M | - | -5.68 % | $ 8.28 M | ||
|
Enochian Biosciences
ENOB
|
56.2 K | - | - | $ 40.5 M |